

# Roche Investor Relations ASCO Planner 2018

## Friday, June 1

---

**Session Title:** Hematologic Malignancies—Plasma Cell Dyscrasia

**Session Type:** Oral Abstract Session

**Date:** Fri, June 1

**Location:** E450

**Time:** 2:45 PM - 5:45 PM

**Speaker Name:** Luciano J. Costa

- **3:57 PM – 4:09 PM**

**Abstract 8004** Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

---

**Session Title:** Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated!

**Session Type:** Clinical Science Symposium

**Date:** Fri, June 1

**Location:** Hall D1

**Time:** 4:30 PM - 6:00 PM

**Speaker Name:** Dong-Wan Kim, MD, PhD

- **4:42 PM - 4:54 PM**

**Abstract 9009** Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

## Saturday, June 2

---

**Session Title:** Genitourinary (Nonprostate) Cancer

**Session Type:** Poster Session

**Date:** Sat, June 2

**Location:** Hall A

**Time:** 8:00 AM - 11:30 AM

**Speaker Name:** Arjun Vasant Balar, MD

- **Abstract 4523** Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. **Poster Board #349**

---

**Session Title:** Pediatric Oncology

**Session Type:** Poster Session

**Date:** Sat, June 2

**Location:** Hall A

**Time:** 8:00 AM - 11:30 AM

**Speaker Name:** Ami Vijay Desai, MD, MSCE

- **Abstract 10536** Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. **Poster Board #209**

## Sunday, June 3

---

**Session Title:** Breast Cancer—Metastatic

**Session Type:** Oral Abstract Session

**Date:** Sun, June 3

**Location:** Hall D2

**Time:** 8:00 AM - 11:00 AM

**Speaker Name:** Jose Baselga, MD, PhD, FASCO; Rebecca Alexandra Dent, MD

- **10:00 AM - 10:12 AM**  
**Abstract LBA1006** Phase III study of taseleisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- **10:24 AM - 10:36 AM**  
**Abstract 1008** Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

---

**Session Title:** Genitourinary (Nonprostate) Cancer

**Session Type:** Oral Abstract Session

**Date:** Sun, June 3

**Location:** Arie Crown Theater

**Time:** 8:00 AM - 11:00 AM

**Speaker Name:** Bernard Escudier, MD; Thomas Powles, MD

- **8:24 AM - 8:36 AM**  
**Abstract 4511** Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

- **10:00 AM - 10:12 AM**

**Abstract 4506** A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

---

**Session Title:** Gastrointestinal (Noncolorectal) Cancer

**Session Type:** Poster Session

**Date:** Sun, June 3

**Location:** Hall A

**Time:** 8:00 AM - 11:30 AM

**Speaker Name:** Stacey Stein, MD

- **Abstract 4074** Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). **Poster Board #263**
- 

**Session Title:** Lung Cancer—Non-Small Cell Metastatic

**Session Type:** Poster Session

**Date:** Sun, June 3

**Location:** Hall A

**Time:** 8:00 AM - 11:30 AM

**Speaker Name:** D. Ross Camidge, MD, PhD; Martin Reck, MD, PhD

- **Abstract 9043** Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. **Poster Board #366**
  - **Abstract 9047** Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). **Poster Board #370**
- 

**Session Title:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**Session Type:** Oral Abstract Session

**Date:** Sun, June 3

**Location:** E450

**Time:** 9:45 AM - 12:45 PM

**Speaker Name:** Laurie Helen Sehn, MD, MPH; Peter Hillmen, M.B., Ch.B.

- **11:45 AM - 11:57 AM**

**Abstract 7507** Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

- **11:57 AM - 12:09 PM**

**Abstract 7508** High, durable minimal residual disease negativity (MRD-) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

---

**Session Title:** Plenary Session Including the Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sun, June 3

**Location:** Hall B1

**Time:** 1:00 PM - 4:00 PM

**Chair and/or Co-Chairs:** Bruce E. Johnson, MD, FASCO; Ann H. Partridge, MD, MPH, FASCO; Daniel F. Hayes, MD, FACP, FASCO, BA; Douglas R. Lowy, MD; Joseph A. Sparano, MD; Lisa A. Carey, MD; Gianni Bisogno, MD; Douglas S. Hawkins, MD; Arnaud Mejean, MD, PhD; Daniel J. George, MD; Gilberto Lopes, MD, MBA; Leena Gandhi, MD, PhD

## Monday, June 4

---

**Session Title:** Lung Cancer—Non-Small Cell Metastatic

**Session Type:** Oral Abstract Session

**Date:** Mon, June 4

**Location:** Hall B1

**Time:** 3:00 PM - 6:00 PM

**Speaker Name:** Robert M. Jotte, MD, PhD; Mark A. Socinski, MD

- **3:00 PM - 3:12 PM**

**Abstract LBA9000** IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

- **3:45 PM - 3:57 PM**

**Abstract 9002** Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

---

**Session Title:** Targeted Therapy in Leukemia

**Session Type:** Clinical Science Symposium

**Date:** Mon, June 4

**Location:** E450

**Time:** 4:30 PM - 6:00 PM

**Speaker Name:** Courtney Denton Dinardo, MD

- **5:06 PM - 5:24 PM**

**Abstract 7010** Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).

## Tuesday, June 5

---

**Session Title:** Tumor Biology

**Session Type:** Oral Abstract Session

**Date:** Tue, June 5

**Location:** S406

**Time:** 8:00 AM - 11:00 AM

**Speaker Name:** Fatema A. Legrand, PhD; Vamsidhar Velcheti, MD; Gracy Crane

- **8:00 AM - 8:12 AM**  
**Abstract 12000** Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- **8:12 AM - 8:24 AM**  
**Abstract 12001** Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-FIRST results.
- **10:00 AM - 10:12 AM**  
**Abstract 12006** Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC).